A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

PHASE2CompletedINTERVENTIONAL
Enrollment

518

Participants

Timeline

Start Date

November 10, 2014

Primary Completion Date

May 26, 2016

Study Completion Date

June 13, 2016

Conditions
Schizophrenia
Interventions
DRUG

BI 409306 100 mg QD

DRUG

BI 498306 50 mg QD

DRUG

Placebo

DRUG

BI 498306 25 mg QD

DRUG

BI 409306 10 mg QD

Trial Locations (43)

110

Taipei City Hospital, Taipei

500

Chang-Hua Christian Hospital, Changhua

704

NCKUH, Tainan City

802

Kai-Syuan Psychiatric Hospital, Kaohsiung City

10312

Richmond Behavioral Associates, Staten Island

11516

Neurobehavioral Research, Inc., Cedarhurst

14618

Finger Lakes Research, Rochester

14623

University of Rochester Medical Center, Rochester

20016

Comprehensive Clinical Development, Washington D.C.

30331

Atlanta Center, Atlanta

32751

Florida Clinical Research Center, Maitland

33161

Behavioral Clinical Research, Inc., North Miami

33319

Innovative Clinical Research, Lauderhill

40629

LVR-Klinikum Düsseldorf, Düsseldorf

50937

Universitätsklinikum Köln (AöR), Cologne

60611

Northwestern University, Chicago

60640

Uptown Research Institute, Chicago

63109

Mid-America Clinical Research, LLC, St Louis

63141

St. Louis Clinical Trials, St Louis

69115

Uniklinikum Heidelberg, Heidelberg

70629

Lake Charles Clinical Trials LLC, Lake Charles

72201

K and S Professional Research Services, LLC, Little Rock

75115

InSite Clinical Research, DeSoto

78754

Community Clinical Research, Inc., Austin

90024

Pacific Institute of Medical Research, Los Angeles

90502

Collaborative Neuroscience Network, Torrance

90703

Comprehensive Clinical Development, Inc., Cerritos

91950

SRSD, Inc. dba Synergy San Diego, National City

92103

Artemis Institute for Clinical Research, LLC, San Diego

92845

Collaborative Neuroscience Network, Garden Grove

92868

NRC Research Institute, Orange

V2A 4M4

Dr. Alexander McIntyre Inc., Penticton

L7R4E2

Depression, Mood Disorders and Schizophrenia Treatment Centr, Burlington

470-1192

Fujita Health University Hospital, Aichi, Toyoake

060-8648

Hokkaido University Hospital, Hokkaido, Sapporo

650-0017

Kobe University Hospital, Hyogo, Kobe

634-8522

Nara Medical University Hospital, Nara, Kashihara

570-8507

Kansai Med. Univ. Med. Ctr., Osaka, Neuropsychiatry, Osaka, Moriguchi-city

842-0192

Hizen Psychiatric Center, Saga, PSY, Saga, Kanzaki-gun

774-0014

Iwaki Clinic, Tokushima, Psychosomatic Medicine, Tokushima, Anan

187-8851

National Center Neurology and Psychiatry, Tokyo, Kodaira

157-8577

Showa University Karasuyama Hospital, Tokyo, Setagaya

142-0054

Showa University East Hospital, Tokyo, Shinagawa

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02281773 - A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment. | Biotech Hunter | Biotech Hunter